Research status of perioperative use of ustekinumab in patients with Crohn's disease
10.3760/cma.j.cn101480-20250515-00076
- VernacularTitle:克罗恩病患者围手术期应用乌司奴单克隆抗体的研究现状
- Author:
Xiaolong GE
1
;
Qian CAO
Author Information
1. 浙江大学医学院附属邵逸夫医院炎症性肠病中心，杭州 310016
- Publication Type:Journal Article
- Keywords:
Crohn's disease;
Ustekinumab;
Perioperative period;
Postoperative complications;
Postoperative recurrence
- From:
Chinese Journal of Inflammatory Bowel Diseases
2025;09(5):384-389
- CountryChina
- Language:Chinese
-
Abstract:
The incidence and prevalence of Crohn's disease (CD) are on the rise in China, and the therapeutic drugs are also rapidly iterating and updating. Ustekinumab (UST), a novel biological agent targeting interleukin-12/23, provides an alternative treatment option for CD patients who have failed conventional drug therapy or anti-tumor necrosis factor-α therapy. With the approval of UST for the treatment of adult CD both at home and abroad, the number of CD patients using UST during the perioperative period has also increased. This article mainly reviews the current evidences on the perioperative use of UST in patients with CD at home and abroad, focusing on the impact of preoperative use of UST on short-term and long-term postoperative complications, and the treatment effect of postoperative use of UST in controlling disease activity.
